公开(公告)号：US20100256160A1

公开(公告)日：2010-10-07

申请号：US12513290

申请日：2007-10-25

申请人： Bernard Laffranchi ,  Jurgen Moll ,  Fabrina Bologna ,  Silvia Comis

发明人： Bernard Laffranchi ,  Jurgen Moll ,  Fabrina Bologna ,  Silvia Comis

IPC分类号： A61K31/496 ,  A61P35/00

CPC分类号： A61K31/4162

摘要： The present invention provides a method of treating a mammal, including humans, suffering from tumour, comprising administering Compound 1 of the formula A or a pharmaceutically acceptable salt thereof, to said mammal by intravenous infusion, characterised in that Compound 1 is conveniently administered employing particular schedules, infusion times and doses which allow a more efficacious treatment. Compound 1 of formula A is an aurora inhibitor, chemical name N-{5-[(2R)-2-methoxy-2-phenylethanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide, and the method is preferably for the treatment of patients having solid tumours or hematopoietic malignant tumours. The use of Compound 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for the treatment of tumours employing particular schedules, infusion times and doses, as well as the use of Compound 1 for treatment of tumours in the same manner are also provided.

摘要翻译： 本发明提供了一种治疗患有肿瘤的哺乳动物（包括人）的方法，其包括通过静脉内输注向所述哺乳动物施用式A化合物1或其药学上可接受的盐，其特征在于化合物1通过特别方法施用 时间表，输液时间和剂量，可进行更有效的治疗。 化学式A的化合物1是化学名称为N- {5 - [（2R）-2-甲氧基-2-苯基乙酰基] -1,4,5,6-四氢吡咯并[3,4-c]吡唑-3 - 基} -4-（4-甲基哌嗪-1-基）苯甲酰胺，该方法优选用于治疗患有实体瘤或造血恶性肿瘤的患者。 化合物1或其药学上可接受的盐和药学上可接受的载体或赋形剂在制备用于治疗使用特定时间表，输注时间和剂量的肿瘤的药物中的用途以及化合物1用于 也提供以相同方式治疗肿瘤。